In the current context with BTZ treatment in Onc-p53 NSCLC cells, we speculate that BTZ-induced ATF3 forms homodimers and binds to the NOXA promoter directly to activate its expression, which we are currently exploring. Here, ATF3 is linked to non-small cell lung carcinoma.